# A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin

Study · id `cardio:ct-nct05275400` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05275400](<https://clinicaltrials.gov/study/NCT05275400>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05275400

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 986 participants.

## Technical summary

Registry record NCT05275400. Randomized; no masking; primary purpose treatment. Start 2022-03-08 (actual); primary completion 2024-05-15 (actual). Results posted on 2025-06-03.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 986 participants (enrolled count; ClinicalTrials.gov record NCT05275400, source copy `cardio:ctgov-nct05275400-2025-06-03`, retrieved 2026-10-26)
- Started: 2022-03-08 (actual) (ClinicalTrials.gov record NCT05275400, source copy `cardio:ctgov-nct05275400-2025-06-03`, retrieved 2026-10-26)
- Primary completion: 2024-05-15 (actual) (ClinicalTrials.gov record NCT05275400, source copy `cardio:ctgov-nct05275400-2025-06-03`, retrieved 2026-10-26)
- Completion: 2024-05-15 (actual) (ClinicalTrials.gov record NCT05275400, source copy `cardio:ctgov-nct05275400-2025-06-03`, retrieved 2026-10-26)
- Results first posted: 2025-06-03 (ClinicalTrials.gov record NCT05275400, source copy `cardio:ctgov-nct05275400-2025-06-03`, retrieved 2026-10-26)
- Countries: United States; Argentina; Hungary; Japan; Poland; Puerto Rico; Slovakia; South Korea; Spain; Taiwan (ClinicalTrials.gov record NCT05275400, source copy `cardio:ctgov-nct05275400-2025-06-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05275400-2025-06-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin
- Condition: Type 2 Diabetes
- Intervention (Drug): Insulin Efsitora Alfa
- Intervention (Drug): Insulin Degludec
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial (`cardio:pubmed-40562047`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 78ea0b5bd5dafd1b30a29de860bcb1d46b6e4bc2464e5418b1377c2c4202bf28
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
